Lupin launches nasal drug for breathing problems in United States | The Financial Express

Lupin launches nasal drug for breathing problems in United States

According to IQVIA MAT September 2022, Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of USD 268 million in the U.S.

Lupin launches nasal drug for breathing problems in United States
The drug will be available in one strength with a fixed dose to be taken once daily. (File)

Global pharma major Lupin Limited on Tuesday announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

According to IQVIA MAT September 2022, Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of USD 268 million in the U.S.

Formoterol oral inhalation is indicated to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease which is a group of lung diseases that includes chronic bronchitis and emphysema.

The drug works by relaxing and opening air passages in the lungs, making it easier to breathe.

ALSO READ | Lupin’s Brazilian subsidiary, MedQuimica acquires rights to 9 brands from Bausch Health

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 29-11-2022 at 13:54 IST